发明名称 Androgen receptor modulating carboxamides
摘要 Compounds of formula (I) or (II); wherein Rx, Rz, R9, R10, R14, R14′, R15, R15′, A and B are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds possess utility as tissue-selective androgen receptor modulators (SARM) and are useful as medicaments in the treatment of prostate cancer and other AR dependent conditions and diseases where AR antagonism is desired.
申请公布号 US8921378(B2) 申请公布日期 2014.12.30
申请号 US201214112727 申请日期 2012.04.20
申请人 Orion Corporation 发明人 Törmäkangas Olli;Wohlfahrt Gerd;Salo Harri;Ramasubramanian Rathna Durga;Patra Pranab Kumar;Martin Arputharaj Ebenezer;Heikkinen Terhi;Vesalainen Anniina;Moilanen Anu;Karjalainen Arja
分类号 A61K31/519;C07D231/14;C07D487/04;C07D403/04;C07D471/04;C07D403/14;C07D401/14;C07D403/12;C07D401/04;C07D413/14;C07D413/12;C07D513/04 主分类号 A61K31/519
代理机构 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP 代理人 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
主权项 1. A compound of formula (I) or (II) wherein ring A is any one of the following groups or tautomers thereof wherein RX is halogen or CF3; RX is hydrogen or halogen; R1 is hydroxy C3-7 alkyl, imidazolyl or —RAOC(O)—RB; RA is C1-7 alkyl; RB is C1-7 alkyl, hydroxy C1-7 alkyl or carboxy C1-7 alkyl; R2 is C1-7 alkyl, C2-7 alkenyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-7 alkyl, methylpyrazolyl or pyrimidinyl; R3 is halogen or pyridinyl; R4 is pyridinyl; R5 is C1-7 alkyl, C2-7 alkenyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-7 alkyl, cyano, hydroxy C1-7 alkyl, oxo C1-7 alkyl, halogen or methylpyrazolyl; R6 is C1-7 alkyl, C2-7 alkenyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-7 alkyl, hydroxy, hydroxy C1-7 alkyl, cyano C1-7 alkyl or C1-7 alkoxycarbamoyl C1-7 alkyl; R7 is hydroxy C4 alkyl; R8 is halogen, C2-7 alkyl, C2-7 alkenyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-7 alkyl, cyano, carboxy, oxo C1-7 alkyl, halo C1-7 alkyl, hydroxy C1-7 alkyl, tetrahydro-2H-thiopyran or —C(O)—NHR20; R9 is hydrogen, hydroxy, halogen, nitro, amino, cyano, oxo, C1-7 alkyl, C2-7 alkenyl, C3-7 cycloalkyl, C1-7 alkoxy, halo C1-7 alkyl, hydroxy C1-7 alkyl, cyano C1-7 alkyl, amino C1-7 alkyl, oxo C1-7 alkyl, C1-7 alkoxy C1-7 alkyl, C1-7 alkylamino, hydroxy C1-7 alkylamino, C1-7 alkoxy C1-7 alkylamino, C1-7 alkylamino C1-7 alkyl, hydroxy C1-7 alkylamino C1-7 alkyl, hydroxyimino C1-7 alkyl, C1-7 alkoxycarbamoyl C1-7 alkyl, —C(O)R11, —OC(O)R17, —NH—C(O)R18—NH—SO2—R19 or an optionally substituted 5-12 membered carbocyclic or heterocyclic ring, each group linked to B-ring via a bond or via a C1-7 alkylene linker; R10 is hydrogen, halogen, C1-7 alkyl, C2-7 alkenyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-7 alkyl, oxo, hydroxy C1-7 alkyl, oxo C1-7 alkyl or an optionally substituted 5 or 6 membered carbocyclic or heterocyclic ring; R11 is hydrogen, hydroxy, C1-7 alkyl, hydroxy C1-7 alkyl, C2-7 alkenyl, C3-7 cycloalkyl, halo C1-7 alkyl, C1-7 alkoxy, NR12R13, or an optionally substituted 5-12 membered carbocyclic or heterocyclic ring; R12 is hydrogen, C1-7 alkyl, C2-7 alkenyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-7 alkyl, C1-7 alkoxy, hydroxy C1-7 alkyl, amino C1-7 alkyl or C1-7 alkyl amino C1-7 alkyl; R13 is hydrogen or C1-7 alkyl; R14 and R15 are, independently, hydrogen or C1-7 alkyl; R14′ and R15′ are, independently, hydrogen or C1-7 alkyl, or R14′ and R15′ together form a bond; R17 is C1-7 alkyl, C2-7 alkenyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-7 alkyl, C1-7 alkoxy, amino C1-7 alkyl, C1-7 alkylamino or C1-7 alkylamino C1-7 alkyl; R18 is C1-7 alkyl, C2-7 alkenyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-7 alkyl, amino C1-7 alkyl, C1-7 alkylamino or C1-7 alkylamino C1-7 alkyl; R19 is C1-7 alkyl, C2-7 alkenyl, C3-7 cycloalkyl or C3-7 cycloalkyl C1-7 alkyl; R20 is hydrogen, C1-7 alkyl, C2-7 alkenyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-7 alkyl or C1-7 alkoxy; R21 is cyano C1-7 alkyl or, in case Rx is CF3, R21 can also be hydroxy C1-7 alkyl; R22 is hydroxy C1-7 alkyl; R23 is C1-7 alkyl or hydroxy C1-7 alkyl; R24 is hydroxy, halogen or C1—, alkoxy; ring B is chosen from any one of the following groups and tautomers thereof or pharmaceutically acceptable salts thereof; with the proviso that the compound of formula (II) is not any of the following compounds: (S)-3-acetyl-N-(1-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-1H-pyrazole-5-carboxamide; (S)—N-(1-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-1-(pyridin-4-yl)-1H-pyrazole-3-carboxamide; (S)—N-(1-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-1-(2-fluoroethyl)-2-methyl-1H-imidazole-4-carboxamide; (S)—N-(1-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-3-(1H-imidazol-4-yl)-1,2,4-oxadiazole-5-carboxamide; (S)-5-acetyl-N-(1-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)isoxazole-3-carboxamide; N—((S)-1-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)isoxazole-3-carboxamide; (S)-5-acetyl-N-(2-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propyl)isoxazole-3-carboxamide; (S)—N-(2-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propyl)-2-methyl-1H-imidazole-4-carboxamide; N—((S)-1-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-3-(1-hydroxyethyl)-1H-pyrazole-5-carboxamide; (R)—N-(1-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-2-methyl-1H-imidazole-4-carboxamide; (S)—N-{1-[3-(3-Chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl]propan-2-yl}-2-methyl-1H-imidazole-4-carboxamide; (S)—N-{1-[3-(3-Chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl]propan-2-yl}-1-methyl-1H-imidazole-4-carboxamide; (S)—N-(1-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-3H-imidazo[4,5-b]pyridine-5-carboxamide; (S)—N-(1-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-2-(pyridin-3-yl)thiazole-4-carboxamide; (S)—N-(1-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-1-(pyridin-3-yl)-1H-pyrazole-3-carboxamide; (S)—N-(1-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-2-methyl-1-(3-oxobutyl)-1H-imidazole-4-carboxamide; (S)—N-(1-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-1-(3-hydroxy-3-methylbutyl)-2-methyl-1H-imidazole-4-carboxamide; (S)—N-(1-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)imidazo[1,2-a]pyridine-2-carboxamide; (S)—N-(1-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-1-(pyridin-3-yl)-1H-imidazole-4-carboxamide; (S)—N-(1-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-2-(2-hydroxypropan-2-yl)oxazole-4-carboxamide; (S)—N-(1-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)imidazo[1,2-a]pyrimidine-2-carboxamide; (S)—N-(1-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-3-fluoroimidazo[1,2-a]pyridine-2-carboxamide; (S)—N-(1-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-4,5,6,7-tetrahydro-2H-indazole-3-carboxamide; (S)—N-(1-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide; (S)—N-(1-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-2,4,6,7-tetrahydropyrano[4,3-c]pyrazole-3-carboxamide; (S)—N-(1-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-1-(6-methylpyridin-2-yl)-1H-imidazole-4-carboxamide; (S)—N-(1-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-6,7-dihydro-4H-pyrano[3,4-d]isoxazole-3-carboxamide; or (S)—N-(1-(3-(3-chloro-4-cyano-5-fluorophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(2-hydroxypropan-2-yl)isoxazole-3-carboxamide.
地址 Espoo FI